Print Print
CKS is no longer commissioned by the National Institute for Health and Clinical Excellence (NICE). NICE remains committed to providing a replacement service for CKS and is currently reviewing its options. In the meantime, although CKS content is now not being maintained, it still remains relevant and will continue to be made available. CKS content was generated under a programme of topic creation and update. To check if the topic you are viewing is current or out of date, please refer to the topic publication details by clicking on the 'How up-to-date is this topic?' link in the left hand menu on individual topic pages.

Obesity - How up-to-date is this topic?
Changes

Version 3.1, revision planned in 2011.

Last revised in September 2007

February 2010 — minor update. Advice on interactions between orlistat and levothyroxine and antiepileptic drugs has been added to the Prescribing information section. Issued in February 2010.

January 2010 — updated. On 21 January 2010 the European Medicines Agency's (EMEA) Committee for Medicinal Products for Human Use (CHMP) recommended the suspension of the Marketing Authorisation for sibutramine (Reductil®) because the benefits no longer outweigh the risks [EMEA, 2010]. This CKS topic has been updated to reflect the EMEA's decision. Recommendations regarding when to consider prescribing sibutramine, as well as prescribing information and prescriptions have been removed. Issued in January 2010.

October 2008 — updated. On 23 October 2008 EMEA CMHP recommended the suspension of the Marketing Authorisation for rimonabant (Acomplia®) because the benefits no longer outweigh the risks [EMEA, 2008]. This CKS topic has been updated to reflect the EMEA's decision. Recommendations regarding when to consider prescribing rimonabant, as well as prescribing information and prescriptions have been removed. Issued in November 2008.

June to September 2007 — converted from PRODIGY guidance to CKS topic structure. The evidence-base has been reviewed in detail, and recommendations are more clearly justified and transparently linked to the supporting evidence.

There have been no major changes to the recommendations. This update incorporates recommendations from the National Institute for Health and Clinical Excellence guideline Obesity: guidance on the prevention, identification, assessment and management of overweight and obesity in adults and children.

© NHS Institute for Innovation and Improvement